Wake Up Call: Three Firms Steer $11.6B Pfizer Deal for Biohaven

In today’s column, Ropes, Sullivan & Cromwell, and Skadden Arps are steering Pfizer’s agreement to pay $148.50 a share for a company that makes migraine treatments; elite litigation boutique Susman Godfrey announced 2022 winners of its awards for law school students of color; contracting platform SirionLabs raised $85 million in funding.

• Leading off, Ropes & Gray is advising Pfizer Inc. on the pharmaceutical giant’s $11.6 billion deal for Biohaven Pharmaceutical Holding Company Ltd., which makes therapies for migraines in adults. Sullivan & Cromwell is advising New Haven, Connecticut-based Biohaven on the transaction, expected to close in early 2023. Skadden Arps ...